Consortium Service Management Group Inc (CSMG) has received an Australian patent for its live biological tissue bonding technology, said Donald S. Robbins, CEO of the company. The patent issuance followed the successful completion of more than 700 human surgeries in clinical trials in Ukraine. Robbins considers the patent issuance a major milestone in the continued development of the company's live biological tissue bonding platform technology.
"The use of the tissue bonding technology makes it possible to simplify the technique of surgical intrusion, operate on an almost dry surgical field, reduce the time of surgery by 30 to 40 per cent, reduce blood loss and increase the reliability of surgeries," commented the chief surgeon heading the Ukraine clinical trials.
The tissue bonding device bonds and reconnects living soft biological tissue without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues, and the technology leaves little or no scar tissue visible to the naked eye after a few months. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CSMG technology bonds and reconnects incised tissue and avoids charring, searing and necrosis, using a low heat delivery method aimed at restoration of the normal functions of the live organs and tissue. United States and other foreign patents are pending, Robbins said. CSMG maintains a team of more than 20 researchers, surgeons, engineers, technicians and clinical test facilities in Ukraine and has offices in Corpus Christi, Texas; Oklahoma City, Oklahoma and Kiev, Ukraine.